StreetInsider.com News Articles

Alkermes (ALKS) PT Raised to $63 at Stifel

Mon, 20 Jul 2026 05:14:47 -0400

Stifel analyst Paul Matteis raised the price target on Alkermes (NASDAQ: ALKS) to $63.00 (from $45.00) while maintaining a Buy rating.

The analyst comments "We are reiterating our Buy rating on ALKS, and we are raising our target price to $63, from $45. Our biggest source of reluctance with the stock here is that expectations for the orexin programs have increased significantly, and, after the CNTA acquisition by LLY, there's some amount of M&A optionality credit priced in to ALKS shares. That said, as we dig into within, we think (1) IH data later this year are likely to be positive,

Alkermes (ALKS) PT Raised to $63 at Stifel

Mon, 20 Jul 2026 05:14:47 -0400

Stifel analyst Paul Matteis raised the price target on Alkermes (NASDAQ: ALKS) to $63.00 (from $45.00) while maintaining a Buy rating.

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Tue, 14 Jul 2026 16:00:00 -0400

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Tue, 14 Jul 2026 16:00:00 -0400

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Tue, 14 Jul 2026 16:00:00 -0400

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Tue, 14 Jul 2026 16:00:00 -0400

Alkermes (ALKS) PT Raised to $57 at TD Cowen

Mon, 13 Jul 2026 09:20:15 -0400

TD Cowen analyst Joseph Thome raised the price target on Alkermes (NASDAQ: ALKS) to $57.00 (from $50.00) while maintaining a Buy rating.

The analyst comments "Today ALKS reported supportive long-term alixorexton data, with wakefulness and sleepiness improvements sustained through ~9 months in NT1/NT2 and no new safety signals. New Week-24 MWT data extend the durability profile presented at SLEEP. Separately, Tris Pharma’s CRL alleviates pressure from a potential once-nightly oxybate competitor. Reiterate Buy and SOTP-based PT goes to $57."

Alkermes (ALKS) PT Raised to $57 at TD Cowen

Mon, 13 Jul 2026 09:20:15 -0400

TD Cowen analyst Joseph Thome raised the price target on Alkermes (NASDAQ: ALKS) to $57.00 (from $50.00) while maintaining a Buy rating.

Alkermes drug shows sustained narcolepsy benefits at nine months

Mon, 13 Jul 2026 07:01:18 -0400

Alkermes plc (NASDAQ: ALKS) reported interim results from an ongoing long-term extension study showing that its investigational drug alixorexton sustained improvements in wakefulness and daytime sleepiness for up to nine months in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).

The interim analysis, based on a May 12, 2026 data cutoff, measured outcomes at week 24 of the long-term extension for participants who had previously completed the Vibrance-1 (NT1) and Vibrance-2 (NT2) phase 2 studies. Alixorexton is an investigational oral orexin 2 receptor agonist not yet approved by regulators.

In NT1 participants, all dose groups achieved a mean observed

Alkermes drug shows sustained narcolepsy benefits at nine months

Mon, 13 Jul 2026 07:01:18 -0400

In NT1 participants, all dose groups achieved a mean observed

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Mon, 13 Jul 2026 07:00:00 -0400

— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 —

— Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained —